Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

KRAS inhibitor

- PMLiVE

CHMP blocks UCB/Amgen’s Evenity approval for osteoporosis

Another obstacle for drug

- PMLiVE

Has Amgen cracked KRAS? First clinical data says maybe

Progess on cancer 'master switch'

- PMLiVE

Encouraging early data for Amgen’s BiTE therapies

Including first-in-man data from prostate cancer drug

- PMLiVE

Amgen buys Danish partner Nuevolution for $167m

Copenhagen-based biotech will remain autonomous

- PMLiVE

So far so good for Amgen’s much-anticipated KRAS inhibitor

Promise to hit previously 'undruggable' target

- PMLiVE

Amgen and UCB’s Evenity finally approved, but with label warnings

Drug unlikely to match Prolia's revenues

- PMLiVE

Novartis and Amgen come to blows over migraine partnership

Amgen seeks to terminate contract

- PMLiVE

Pfizer gets EU nod for Tagrisso rival Vizimpro

Five year survival still only 12%

- PMLiVE

Amgen, Servier heart failure drug clears trial hurdle

Drug could be a blockbuster - if it hits key endpoints

- PMLiVE

Tecentriq combo gains European NSCLC approval

Triple combination approved after targeted therapy

- PMLiVE

Amgen, Servier start second phase 3 trial of heart failure hope

Treatment is one of few in underserved area

- PMLiVE

Pfizer closes on EU approval of lung cancer drug Vizimpro

And AZ claims first with Forxiga in T1 diabetes

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links